ArticleCureus2023
A Case of Non-purpuric Neonatal Alloimmune Thrombocytopenia Secondary to ABO Incompatibility.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neonatal alloimmune thrombocytopenia (NAIT) is a condition in which maternal IgG antibodies are directed against fetal platelets and cross the placenta, destroying fetal thrombocytes. It is typically caused by maternal alloimmunization to human leukocyte antigens (HLA). ABO incompatibility, on the other hand, is a rare cause of NAIT due to the variable expression of ABO antigens on platelets. Here, we present the case of a first-time mother (O+) who delivered a 37-week 0-day gestation newborn (B+) that was anemic and jaundiced with critically high total bilirubin levels. This required the initiation of phototherapy and intravenous immunoglobulins. Despite treatment, jaundice was slow to improve. Given infectious concerns, a complete white blood cell count was ordered. Incidentally, it revealed severe thrombocytopenia. Platelet transfusions were administered, although only minimal improvement was observed. This warranted maternal testing for antibodies to HLA-Ia/IIa, HLA-IIb/IIIa, and HLA-Ib/IX antigens given suspected NAIT. Results returned negative. Due to the severity of the condition, patient care was continued at a tertiary facility. When screening for NAIT, special consideration should be given to type O mothers with ABO incompatibility to their fetus - they can uniquely make IgG against A or B antigens, which, unlike IgM and IgA, can cross the placenta and cause potential sequelae harming the newborn. Early recognition and timely management of NAIT are important to prevent certain complications, such as fatal intracranial hemorrhage and developmental delay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.